No The Lancet, o cálculo da estratégia da polipílula para prevenção primária e secundária da doença cardiovascular. A proposta é administrar aspirina+estatina+hidroclorotiazida+enalapril a indivíduos com risco elevado de doença cardiovascular. Para aqueles que já sofreram infarto do miocárdio se acrescentaria o atenolol. O estudo apresentado é um simulação para países de baixa e e média renda, mas poderá ser também um bom exercício para uma política ampla de prevenção cardiovascular. Infelizmente, o texto no The Lancet é somente para assinantes.
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs
Stephen S Lim, Thomas A Gaziano, Emmanuela Gakidou, K Srinath Reddy, Farshad Farzadfar, Rafael Lozano, Anthony Rodgers
In 2005, a global goal of reducing chronic disease death rates by an additional 2% per year was established. Scaling up coverage of evidence-based interventions to prevent cardiovascular disease in high-risk individuals in low-income and middle-income countries could play a major part in reaching this goal. We aimed to estimate the number of deaths that could be averted and the fi nancial cost of scaling up, above current coverage levels, a multidrug regimen for prevention of cardiovascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries. Identifi cation of individuals was limited to those already accessing health services, and treatment eligibility was based on the presence of existing cardiovascular disease or absolute risk of cardiovascular disease by use of easily measurable risk factors. Over a 10-year period, scaling up this multidrug regimen could avert 17·9 million deaths from cardiovascular disease (95% uncertainty interval 7·4 million–25·7 million). 56% of deaths averted would be in those younger than 70 years, with more deaths averted in women than in men owing to larger absolute numbers of women at older ages. The 10-year financial cost would be US$47 billion ($33 billion–$61 billion) or an average yearly cost per head of $1·08 ($0·75–1·40), ranging from $0·43 to $0·90 across low-income countries and from $0·54 to $2·93 across middle-income countries. This package could effectively meet three-quarters of the proposed global goal with a moderate increase in health expenditure.
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs
Stephen S Lim, Thomas A Gaziano, Emmanuela Gakidou, K Srinath Reddy, Farshad Farzadfar, Rafael Lozano, Anthony Rodgers
In 2005, a global goal of reducing chronic disease death rates by an additional 2% per year was established. Scaling up coverage of evidence-based interventions to prevent cardiovascular disease in high-risk individuals in low-income and middle-income countries could play a major part in reaching this goal. We aimed to estimate the number of deaths that could be averted and the fi nancial cost of scaling up, above current coverage levels, a multidrug regimen for prevention of cardiovascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries. Identifi cation of individuals was limited to those already accessing health services, and treatment eligibility was based on the presence of existing cardiovascular disease or absolute risk of cardiovascular disease by use of easily measurable risk factors. Over a 10-year period, scaling up this multidrug regimen could avert 17·9 million deaths from cardiovascular disease (95% uncertainty interval 7·4 million–25·7 million). 56% of deaths averted would be in those younger than 70 years, with more deaths averted in women than in men owing to larger absolute numbers of women at older ages. The 10-year financial cost would be US$47 billion ($33 billion–$61 billion) or an average yearly cost per head of $1·08 ($0·75–1·40), ranging from $0·43 to $0·90 across low-income countries and from $0·54 to $2·93 across middle-income countries. This package could effectively meet three-quarters of the proposed global goal with a moderate increase in health expenditure.
Um comentário:
Muito interessante, e ao mesmo tempo preocupante, a tentativa de unir em uma única pípula mágica drogas que tratam os pacientes cardiopatas. Acho interessante postar aqui meu comnetário a seguir, pois sou estudante e no exato momento minhas atenções estão voltadas no tratamento de pacientes cardiopatas, em foco os coronarianos. No caso dos pacientes já infartados, não seria interssante adicionar uma outra droga que não o tão conhecido atenolol? No caso, acho que é interssante abrir nossas mentes para outras substâncias, mais novas e comprovadamente eficazes. Digo por rexemplo a trimetazidina, uma substância única, pois até hoje não tive conhecimento d enhum outra droga que atuasse no metabolismo cardíaco celular, uma vez que o processo de isquemia vem acontecendo lenta e progressivamente, nada mais indicado do que tratar o célula que desde o começo já começa a se degenerar? No mínimo interessante não? Posso estar com essa palpite me aventurando em aguás ja repousadas, mas na teoria funcionaria muito bem uma combinação com esse propósito.
Postar um comentário